Back

Calibrated ADAMTS13 inhibition prevents cardiovascular shear coagulopathy

Saito, K.; Isozumi, N.; Shiraishi, Y.; Hattori, Y.; Sakai, K.; Ueda, T.; Hamamura, A.; Imamura, R.; Kayashima, M.; Nakano, K.; Yambe, T.; Kumeta, H.; Shigehisa, R.; Mori, M.; Imamura, T.; Nakanishi, M.; Oda, M.; Kanemura, S.; Okumura, M.; Niwa, T.; Martel, A.; Porcar, L.; Morishima, K.; Okuda, A.; Sugiyama, M.; Takatsuka, M.; Tomimatsu, N.; Saio, T.; Hikoso, S.; Mori, E.; Matsumoto, M.

2026-08-04 biochemistry
10.64898/2026.08.03.742456 bioRxiv
Show abstract

Mechanical circulatory support essential for managing severe heart failure frequently triggers bleeding complications, driven by shear stress-induced over-proteolysis of von Willebrand factor (VWF) by ADAMTS13. Inhibiting ADAMTS13 presents a rationale to treat this condition, known as acquired von Willebrand syndrome (AVWS). However, conventional therapeutic strategies remain limited due to the risk of triggering thrombotic thrombocytopenic purpura. Here we show that HA10, a humanized anti-ADAMTS13 antibody, preserves a residual level of ADAMTS13 activity above the thrombosis-associated threshold. Multimodal structural and biophysical analyses--including NMR, SAXS, and SANS--revealed that HA10 bound to the disintegrin-like domain of ADAMTS13, dynamically competing with VWF while leaving 10- 20% residual enzymatic activity. The therapeutic efficacy and safety of HA10 were verified in non-human primate models of AVWS. Our findings establish a novel paradigm of enzymatic calibration rather than complete blockade, offering a mechanistically targeted and safe therapeutic approach for cardiovascular bleeding.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.